- Cardiovascular disease (CVD) risk increases in patients taking statins who have increased levels of lipoprotein(a) (LPA) at baseline or on treatment, regardless of other CVD risk factors.
Why this matters
- Initiating statin therapy had no appreciable effect on LPA levels.
- The risk association between CVD and LPA was “approximately linear.”
- With baseline LPA of 50 mg/dL or higher, CVD aHR was 1.31 (95% CI, 1.08-1.58).
- The risk at that cutoff was slightly different for on-statin patients: aHR, 1.43 (95% CI, 1.15-1.76).
- Very similar HRs with multivariate adjustment.
- In fact, the on-statin risk was high vs on-placebo risk (Pinteraction=.010).
- Risk also higher in younger age groups (P=.008).
- Meta-analysis of patient-level data from 7 randomized, placebo-controlled trials of statins (n=29,069 in the analysis).
- HRs calculated for cardiovascular events (nonfatal/fatal coronary heart disease, stroke, revascularization procedures).
- Funding: Novartis Pharma AG.
- 35% of patients from included trials were excluded.
- Some interstudy heterogeneity.